Targeted DNA Mutagenesis for the Cure of Chronic Viral Infections

ABSTRACT Human immunodeficiency virus type 1 (HIV-1), hepatitis B virus (HBV), and herpes simplex virus (HSV) have been incurable to date because effective antiviral therapies target only replicating viruses and do not eradicate latently integrated or nonreplicating episomal viral genomes. Endonucleases that can target and cleave critical regions within latent viral genomes are currently in development. These enzymes are being engineered with high specificity such that off-target binding of cellular DNA will be absent or minimal. Imprecise nonhomologous-end-joining (NHEJ) DNA repair following repeated cleavage at the same critical site may permanently disrupt translation of essential viral proteins. We discuss the benefits and drawbacks of three types of DNA cleavage enzymes (zinc finger endonucleases, transcription activator-like [TAL] effector nucleases [TALENs], and homing endonucleases [also called meganucleases]), the development of delivery vectors for these enzymes, and potential obstacles for successful treatment of chronic viral infections. We then review issues regarding persistence of HIV-1, HBV, and HSV that are relevant to eradication with genome-altering approaches.

[1]  J. Karn,et al.  Epigenetic Silencing of Human Immunodeficiency Virus (HIV) Transcription by Formation of Restrictive Chromatin Structures at the Viral Long Terminal Repeat Drives the Progressive Entry of HIV into Latency , 2008, Journal of Virology.

[2]  Matthew J. Moscou,et al.  A Simple Cipher Governs DNA Recognition by TAL Effectors , 2009, Science.

[3]  A. Scharenberg,et al.  Successful Targeting and Disruption of an Integrated Reporter Lentivirus Using the Engineered Homing Endonuclease Y2 I-AniI , 2011, PloS one.

[4]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[5]  S. Dandekar,et al.  Antiviral Therapy during Primary Simian Immunodeficiency Virus Infection Fails To Prevent Acute Loss of CD4+ T Cells in Gut Mucosa but Enhances Their Rapid Restoration through Central Memory T Cells , 2008, Journal of Virology.

[6]  F. Chisari,et al.  High-level hepatitis B virus replication in transgenic mice , 1995, Journal of virology.

[7]  Geoffrey Dusheiko,et al.  The role of cells refractory to productive infection in acute hepatitis B viral dynamics , 2007, Proceedings of the National Academy of Sciences.

[8]  D. Tyrrell,et al.  Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Rock,et al.  Latent herpes simplex virus type 1 DNA contains two copies of the virion DNA joint region , 1985, Journal of virology.

[10]  D. Snydman.  A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B , 2007 .

[11]  D. Burns,et al.  Extrahepatic hepatitis B virus DNA sequences in patients with acute hepatitis B infection , 1990, Hepatology.

[12]  Anitha Rao,et al.  RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma , 2010, Science Translational Medicine.

[13]  G. Nabel,et al.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells , 1987, Nature.

[14]  S. Straus,et al.  Laser-Capture Microdissection: Refining Estimates of the Quantity and Distribution of Latent Herpes Simplex Virus 1 and Varicella-Zoster Virus DNA in Human Trigeminal Ganglia at the Single-Cell Level , 2005, Journal of Virology.

[15]  Alan S. Perelson,et al.  Modeling Latently Infected Cell Activation: Viral and Latent Reservoir Persistence, and Viral Blips in HIV-infected Patients on Potent Therapy , 2009, PLoS Comput. Biol..

[16]  A. Dejean,et al.  Detection of hepatitis B virus DNA in pancreas, kidney and skin of two human carriers of the virus. , 1984, The Journal of general virology.

[17]  F. Chisari,et al.  The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response , 1996, Nature Medicine.

[18]  L. J. Perry,et al.  The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. , 1988, The Journal of general virology.

[19]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  F. Ahmad,et al.  CNS drug delivery systems: novel approaches. , 2009, Recent patents on drug delivery & formulation.

[21]  H. Gendelman,et al.  Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. , 1986, Science.

[22]  A. Barzilai,et al.  The role of the DNA damage response in neuronal development, organization and maintenance. , 2008, DNA repair.

[23]  Ayman El-Kattan,et al.  Current advances in delivery of biotherapeutics across the blood-brain barrier. , 2011, Current drug discovery technologies.

[24]  C. Van Lint,et al.  HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals , 2010, Science.

[25]  R. Purcell,et al.  Dynamics of hepatitis B virus clearance in chimpanzees. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. Thiel,et al.  Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. , 2011, Blood.

[27]  Barbara Ruozi,et al.  Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. , 2011, Nanomedicine.

[28]  Pratima Chowdary,et al.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. , 2011, The New England journal of medicine.

[29]  E. Conseiller,et al.  Meganuclease-mediated Inhibition of HSV1 Infection in Cultured Cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  R. Willson.  Extrahepatic manifestations of chronic viral hepatitis. , 1997, The American journal of gastroenterology.

[31]  Toni Cathomen,et al.  Zinc-finger nucleases for somatic gene therapy: the next frontier. , 2011, Human gene therapy.

[32]  A. Fauci,et al.  Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. , 1986, Science.

[33]  S. Holland,et al.  Diverse Herpes Simplex Virus Type 1 Thymidine Kinase Mutants in Individual Human Neurons and Ganglia , 2007, Journal of Virology.

[34]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[35]  G. Dressler,et al.  Latent herpes simplex virus type 1 DNA is not extensively methylated in vivo. , 1987, The Journal of general virology.

[36]  T. Bergström,et al.  Phylogenetic Analysis of Clinical Herpes Simplex Virus Type 1 Isolates Identified Three Genetic Groups and Recombinant Viruses , 2004, Journal of Virology.

[37]  J. Schiffer,et al.  The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. , 2011, The Journal of infectious diseases.

[38]  Toni Cathomen,et al.  Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases , 2007, Nature Biotechnology.

[39]  T. Margolis,et al.  Herpes Simplex Virus Type 2 (HSV-2) Establishes Latent Infection in a Different Population of Ganglionic Neurons than HSV-1: Role of Latency-Associated Transcripts , 2006, Journal of Virology.

[40]  Willson Ra.  Extrahepatic manifestations of chronic viral hepatitis , 1997 .

[41]  Implementation of newborn hepatitis B vaccination--worldwide, 2006. , 2008, MMWR. Morbidity and mortality weekly report.

[42]  B. Moss,et al.  Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens , 1992, Journal of virology.

[43]  P. Hanawalt,et al.  Terminally Differentiated Human Neurons Repair Transcribed Genes but Display Attenuated Global DNA Repair and Modulation of Repair Gene Expression , 2000, Molecular and Cellular Biology.

[44]  Sa Azin,et al.  An overview on the 2008 UNAIDS Report on the 2008 UNAIDS Report on the Global AIDS Epidemic. , 2010 .

[45]  C. Gibbs,et al.  Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.

[46]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[47]  D. Tyrrell,et al.  Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo , 1996, Hepatology.

[48]  J. Hauber,et al.  In vitro evolution and analysis of HIV-1 LTR-specific recombinases. , 2011, Methods.

[49]  M. Shapiro,et al.  Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.

[50]  A. Ellison,et al.  Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[52]  O. Yang,et al.  A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. , 2010, Blood.

[53]  D. Ganem,et al.  The role of envelope proteins in hepatitis B virus assembly. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[54]  V. Pasquetto,et al.  Intracellular Hepatitis B Virus Nucleocapsids Survive Cytotoxic T-Lymphocyte-Induced Apoptosis , 2000, Journal of Virology.

[55]  Jens Boch,et al.  Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors , 2009, Science.

[56]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[57]  A. Wald,et al.  Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. , 2011, The Journal of infectious diseases.

[58]  Hans-Peter Kiem,et al.  Hematopoietic-stem-cell-based gene therapy for HIV disease. , 2012, Cell stem cell.

[59]  J. Hauber,et al.  HIV-1 Proviral DNA Excision Using an Evolved Recombinase , 2007, Science.

[60]  D. Milich,et al.  Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection , 2003, Hepatology.

[61]  L. Naldini.  Ex vivo gene transfer and correction for cell-based therapies , 2011, Nature Reviews Genetics.

[62]  D. McGeoch,et al.  The Genome Sequence of Herpes Simplex Virus Type 2 , 1998, Journal of Virology.

[63]  J. Zeh,et al.  Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. , 1997, The Journal of clinical investigation.

[64]  A. McCaffrey,et al.  Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  P. Pontisso,et al.  Detection of hepatitis B virus DNA in mononuclear blood cells. , 1984, British medical journal.

[66]  A. Wald,et al.  Persistence of HIV-1 Receptor-Positive Cells after HSV-2 Reactivation: A Potential Mechanism for Increased HIV-1 Acquisition , 2009, Nature Medicine.

[67]  Luigi Naldini,et al.  Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.

[68]  Erin L. Doyle,et al.  Targeting DNA Double-Strand Breaks with TAL Effector Nucleases , 2010, Genetics.

[69]  T. Chun,et al.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  P. Rouet,et al.  Double-strand breaks at the target locus stimulate gene targeting in embryonic stem cells. , 1995, Nucleic acids research.

[71]  G. Bocharov,et al.  Recombination: Multiply infected spleen cells in HIV patients , 2002, Nature.

[72]  P. Tunbäck,et al.  Asymptomatically shed recombinant herpes simplex virus type 1 strains detected in saliva. , 2009, The Journal of general virology.

[73]  G. Carosi,et al.  Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. , 2009, Journal of hepatology.

[74]  Jon Cohen.  Immunology. Painful failure of promising genital herpes vaccine. , 2010, Science.

[75]  T. Bergström,et al.  Divergence and Recombination of Clinical Herpes Simplex Virus Type 2 Isolates , 2007, Journal of Virology.

[76]  K. Walters,et al.  Half-Life of the Duck Hepatitis B Virus Covalently Closed Circular DNA Pool In Vivo following Inhibition of Viral Replication , 2002, Journal of Virology.

[77]  F. Bushman,et al.  Engineering HIV-Resistant Human CD4+ T Cells with CXCR4-Specific Zinc-Finger Nucleases , 2011, PLoS pathogens.

[78]  Y. Shaul,et al.  The "Trojan horse" model-delivery of anti-HBV small interfering RNAs by a recombinant HBV vector. , 2009, Biochemical and biophysical research communications.

[79]  C. Baty,et al.  Noncytotoxic Lytic Granule–Mediated CD8+ T Cell Inhibition of HSV-1 Reactivation from Neuronal Latency , 2008, Science.

[80]  D. Nickle,et al.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.

[81]  B. Stoddard,et al.  Homing endonucleases: from microbial genetic invaders to reagents for targeted DNA modification. , 2011, Structure.

[82]  J. Bartolomé,et al.  Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection , 2003, Journal of medical virology.

[83]  F. Chisari,et al.  Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[84]  J. Schiffer,et al.  New concepts in understanding genital herpes , 2009, Current infectious disease reports.

[85]  R. Siliciano,et al.  Resting CD4+ T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes , 2004, Journal of Virology.

[86]  G. Nabel,et al.  Inhibition of recombinant human immunodeficiency virus type 1 replication by a site-specific recombinase , 1997, Journal of Virology.

[87]  Lawrence Corey,et al.  Once-daily valacyclovir to reduce the risk of transmission of genital herpes* , 2004, The New England journal of medicine.

[88]  D. Snydman.  Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BLai C-L, for the BEHoLD AI463027 Study Group (Queen Mary Hosp, Hong Kong; et al) N Engl J Med 354:1011–1020, 2006§ , 2007 .

[89]  Jennifer D. Hall,et al.  Impaired Mismatch Extension by a Herpes Simplex DNA Polymerase Mutant with an Editing Nuclease Defect* , 1998, The Journal of Biological Chemistry.

[90]  Michael T. Certo,et al.  Optimization of in vivo activity of a bifunctional homing endonuclease and maturase reverses evolutionary degradation , 2008, Nucleic acids research.

[91]  D. Bloom,et al.  Tissue-Specific Splicing of the Herpes Simplex Virus Type 1 Latency-Associated Transcript (LAT) Intron in LAT Transgenic Mice , 2006, Journal of Virology.

[92]  H. Blum,et al.  Generation of Covalently Closed Circular DNA of Hepatitis B Viruses via Intracellular Recycling Is Regulated in a Virus Specific Manner , 2010, PLoS pathogens.

[93]  Jonathan A C Sterne,et al.  HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis , 2006, The Lancet.

[94]  Lihua Julie Zhu,et al.  Zinc finger protein-dependent and -independent contributions to the in vivo off-target activity of zinc finger nucleases , 2010, Nucleic Acids Res..

[95]  Alessandro Aiuti,et al.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.

[96]  S. Kaneko,et al.  Detection of Hepatitis B and C Viruses in Almost All Hepatocytes by Modified PCR-Based In Situ Hybridization , 2010, Journal of Clinical Microbiology.

[97]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[98]  D. Nickle,et al.  Importance and detection of virus reservoirs and compartments of HIV infection. , 2003, Current opinion in microbiology.

[99]  John O. Woods,et al.  Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy , 2009, Journal of Virology.

[100]  P. Rouet,et al.  Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[101]  Christopher D Pilcher,et al.  Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. , 2006, JAMA.

[102]  Christine Hogan,et al.  Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract , 2004, The Journal of experimental medicine.

[103]  Tara L. Kieffer,et al.  Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. , 2004, The Journal of infectious diseases.

[104]  Sheng Huang,et al.  TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain , 2010, Nucleic Acids Res..

[105]  F. Zoulim,et al.  Woodchuck hepatitis virus X protein is required for viral infection in vivo , 1994, Journal of virology.

[106]  M. Wayengera.  Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: novel HSV-2 vaccine/therapy precursors , 2011, Theoretical Biology and Medical Modelling.

[107]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[108]  Pilar Blancafort,et al.  Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins. , 2003, Biochemistry.

[109]  P. Duesberg.  HIV Latency , 1993, Bio/Technology.

[110]  A. Perelson,et al.  Modeling complex decay profiles of hepatitis B virus during antiviral therapy , 2009, Hepatology.

[111]  D. Pillay,et al.  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load , 2010, AIDS.

[112]  K. Walters,et al.  Superinfection Exclusion in Duck Hepatitis B Virus Infection Is Mediated by the Large Surface Antigen , 2004, Journal of Virology.

[113]  P. Darke,et al.  Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus protease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[114]  J. Nolta,et al.  Specific Transduction of HIV-Susceptible Cells for CCR5 Knockdown and Resistance to HIV Infection: A Novel Method for Targeted Gene Therapy and Intracellular Immunization , 2009, Journal of acquired immune deficiency syndromes.

[115]  M. Nassal.  Hepatitis B viruses: reverse transcription a different way. , 2008, Virus research.

[116]  Chien-Jen Chen,et al.  Hepatitis B e antigen and the risk of hepatocellular carcinoma. , 2002, The New England journal of medicine.

[117]  S. Hughes,et al.  Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 Replication , 2010, Journal of Virology.

[118]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[119]  P. Marion,et al.  Exploring gene‐deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice , 2008, The journal of gene medicine.

[120]  Robert F. Siliciano,et al.  In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency , 1995, Nature Medicine.

[121]  I. Alexander,et al.  Adeno-associated virus and lentivirus vectors mediate efficient and sustained transduction of cultured mouse and human dorsal root ganglia sensory neurons. , 2001, Human gene therapy.

[122]  S. Morrison,et al.  HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. , 2011, Cell host & microbe.

[123]  Susan Carpenter,et al.  Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes , 2011, Nucleic acids research.

[124]  S J Gange,et al.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.

[125]  W. Byarugaba,et al.  Identification of restriction endonuclease with potential ability to cleave the HSV-2 genome: Inherent potential for biosynthetic versus live recombinant microbicides , 2008, Theoretical Biology and Medical Modelling.

[126]  H. Fujita.  Latent multiple infections by herpes simplex virus type 1. , 2000, The Kurume medical journal.

[127]  Alan S. Perelson,et al.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.

[128]  J. Rajčáni,et al.  Peculiarities of Herpes Simplex Virus (HSV) Transcription: An overview , 2004, Virus Genes.

[129]  D. Nickle,et al.  Evolutionary Indicators of Human Immunodeficiency Virus Type 1 Reservoirs and Compartments , 2003, Journal of Virology.

[130]  Ruy M Ribeiro,et al.  Hepatitis B virus kinetics and mathematical modeling. , 2004, Seminars in liver disease.

[131]  R. Herzog.  Recent advances in hepatic gene transfer: more efficacy and less immunogenicity. , 2005, Current opinion in drug discovery & development.

[132]  L. M. Mansky,et al.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.

[133]  Wei Shao,et al.  Majority of CD4+ T cells from peripheral blood of HIV-1–infected individuals contain only one HIV DNA molecule , 2011, Proceedings of the National Academy of Sciences.

[134]  Dana Carroll,et al.  Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.

[135]  J. Glorioso,et al.  Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. , 2004, Annual review of microbiology.

[136]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[137]  D. Bloom,et al.  Specific Histone Tail Modification and Not DNA Methylation Is a Determinant of Herpes Simplex Virus Type 1 Latent Gene Expression , 2004, Journal of Virology.

[138]  T. Wright,et al.  Clinical aspects of hepatitis B virus infection , 1993, The Lancet.

[139]  E. Verdin,et al.  Epigenetic Regulation of HIV-1 Latency by Cytosine Methylation , 2009, PLoS pathogens.

[140]  A. Wald,et al.  Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes , 2007, Acta obstetricia et gynecologica Scandinavica.

[141]  A. Osterhaus,et al.  Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia , 2007, Proceedings of the National Academy of Sciences.

[142]  M. Purdy,et al.  Supragenotypic groups of the hepatitis B virus genome. , 2008, The Journal of general virology.

[143]  Vanessa Taupin,et al.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.

[144]  Ron Milo,et al.  Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy , 2011, Nature.

[145]  Xiao Xiao,et al.  Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[146]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[147]  S. Takada,et al.  Quantitative analysis of genomic polymorphism of herpes simplex virus type 1 strains from six countries: studies of molecular evolution and molecular epidemiology of the virus. , 1994, The Journal of general virology.

[148]  Claus O. Wilke,et al.  Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells , 2006, Journal of Virology.

[149]  M. Lederman,et al.  The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial , 2010, PLoS medicine.

[150]  R. Siliciano,et al.  HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. , 2012, The Journal of infectious diseases.

[151]  Alan S. Perelson,et al.  Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus , 2010, Science Translational Medicine.

[152]  S. Deshmane,et al.  During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure , 1989, Journal of virology.

[153]  S. Fan,et al.  Molecular therapeutics of HBV. , 2003, Current gene therapy.

[154]  F. Zoulim,et al.  Molecular Genetics of HBV Infection , 2010, Antiviral Therapy.

[155]  M. Kay,et al.  Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[156]  K. Reddy,et al.  Extrahepatic manifestations of chronic viral hepatitis , 2001, Current gastroenterology reports.

[157]  M. Porteus,et al.  Gene editing: not just for translation anymore , 2011, Nature Methods.

[158]  C. Mahé,et al.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? , 2002, AIDS.

[159]  E. Rebar,et al.  Genome editing with engineered zinc finger nucleases , 2010, Nature Reviews Genetics.

[160]  M. Dandri,et al.  Chimeric mouse model of hepatitis B virus infection. , 2012, Journal of hepatology.

[161]  S. Locarnini,et al.  The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes , 1995, Journal of virology.

[162]  M. Kay,et al.  Assessment of recombinant adenoviral vectors for hepatic gene therapy. , 1993, Human gene therapy.

[163]  G. Learn,et al.  Compartmentalization of HIV-1 within the Female Genital Tract Is Due to Monotypic and Low-Diversity Variants Not Distinct Viral Populations , 2009, PloS one.

[164]  T. Merigan,et al.  Evolution of recurrent herpes simplex lesions. An immunohistologic study. , 1985, The Journal of clinical investigation.

[165]  K. Crandall,et al.  Characterization of the Follicular Dendritic Cell Reservoir of Human Immunodeficiency Virus Type 1 , 2008, Journal of Virology.

[166]  R. Siliciano,et al.  Short communication: dynamic constraints on the second phase compartment of HIV-infected cells. , 2011, AIDS research and human retroviruses.

[167]  C. Van Lint,et al.  Transcriptional activation and chromatin remodeling of the HIV‐1 promoter in response to histone acetylation. , 1996, The EMBO journal.

[168]  Claus O Wilke,et al.  Limits on Replenishment of the Resting CD4+ T Cell Reservoir for HIV in Patients on HAART , 2007, PLoS pathogens.

[169]  D. Tyrrell,et al.  Zinc Finger Proteins Designed To Specifically Target Duck Hepatitis B Virus Covalently Closed Circular DNA Inhibit Viral Transcription in Tissue Culture , 2008, Journal of Virology.

[170]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[171]  D. Follmann,et al.  CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. , 2010, The Journal of infectious diseases.

[172]  R. Schinazi,et al.  Simian immunodeficiency virus macaque models of HIV latency , 2011, Current opinion in HIV and AIDS.

[173]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[174]  J. Cohen,et al.  Rates of Reactivation of Latent Herpes Simplex Virus from Mouse Trigeminal Ganglia Ex Vivo Correlate Directly with Viral Load and Inversely with Number of Infiltrating CD8+ T Cells , 2007, Journal of Virology.

[175]  Moriah L. Szpara,et al.  Sequence Variability in Clinical and Laboratory Isolates of Herpes Simplex Virus 1 Reveals New Mutations , 2010, Journal of Virology.

[176]  Lin Shen,et al.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.

[177]  Irvin S Y Chen,et al.  Inhibition of HIV‐1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction , 2010, The journal of gene medicine.

[178]  T. Quinn,et al.  Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. , 2003, The Journal of infectious diseases.

[179]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[180]  Tina Lenasi,et al.  Transcriptional interference antagonizes proviral gene expression to promote HIV latency. , 2008, Cell host & microbe.

[181]  R. Siliciano,et al.  A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs , 2011, Science Translational Medicine.

[182]  J. Summers,et al.  Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells , 1986, Cell.

[183]  Dale L. Greiner,et al.  T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice , 2008, Cell.

[184]  A. Mocroft,et al.  Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV , 2010, AIDS.

[185]  M. I. Barrasa,et al.  Apoptosis and Regeneration of Hepatocytes during Recovery from Transient Hepadnavirus Infections , 2000, Journal of Virology.

[186]  M. Wick,et al.  Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection , 1993, Hepatology.

[187]  C. Ukomadu,et al.  Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[188]  Joan M. Block,et al.  Underestimation of chronic hepatitis B virus infection in the United States of America , 2007, Journal of viral hepatitis.

[189]  A. Wald,et al.  Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. , 2002, The Journal of infectious diseases.

[190]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[191]  A. Minson,et al.  Detection of herpes simplex virus-specific DNA sequences in latently infected mice and in humans , 1986, Journal of virology.

[192]  P. Krause,et al.  Spread of Herpes Simplex Virus to the Spinal Cord Is Independent of Spread to Dorsal Root Ganglia , 2010, Journal of Virology.

[193]  Erin L. Doyle,et al.  Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting , 2011, Nucleic acids research.

[194]  D. McDermott,et al.  CCR5 deficiency increases risk of symptomatic West Nile virus infection , 2006, The Journal of experimental medicine.

[195]  Matthew C Strain,et al.  Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. , 2005, The Journal of infectious diseases.

[196]  James Riddell,et al.  HIV–1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs , 2010, Nature Medicine.

[197]  W. Halford,et al.  ICP0, ICP4, or VP16 Expressed from Adenovirus Vectors Induces Reactivation of Latent Herpes Simplex Virus Type 1 in Primary Cultures of Latently Infected Trigeminal Ganglion Cells , 2001, Journal of Virology.

[198]  Jay H. Konieczka,et al.  Evolution of variants of yeast site-specific recombinase Flp that utilize native genomic sequences as recombination target sites , 2006, Nucleic acids research.

[199]  J. Farrar,et al.  Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. , 2011, AIDS.

[200]  J. Koskinas,et al.  Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients , 2006, Hepatology.

[201]  S. Litwin,et al.  INAUGURAL ARTICLES: Hepatocyte turnover during resolution of a transient hepadnaviral infection , 2003 .

[202]  David Baker,et al.  Computational reprogramming of homing endonuclease specificity at multiple adjacent base pairs , 2010, Nucleic acids research.

[203]  D. Peer,et al.  RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[204]  F. Hecht,et al.  Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. , 2012, The Journal of infectious diseases.

[205]  B. Franza,et al.  The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV , 1988, Cell.

[206]  Fujie Xu,et al.  Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. , 2006, JAMA.

[207]  E. Thiel,et al.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.

[208]  P. Marion,et al.  Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. , 2008, Human gene therapy.

[209]  Yan Zhou,et al.  T Cells + Cd4 Type 1 Decay following Entry into Resting Kinetics of Human Immunodeficiency Virus , 2004 .

[210]  P. Luciw,et al.  Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[211]  J. Marrero,et al.  Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice , 2011, Hepatology.

[212]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[213]  Kai Rothkamm,et al.  Pathways of DNA Double-Strand Break Repair during the Mammalian Cell Cycle , 2003, Molecular and Cellular Biology.

[214]  G. Learn,et al.  Increased mutations in Env and Pol suggest greater HIV-1 replication in sputum-derived viruses compared with blood-derived viruses , 2009, AIDS.

[215]  S. Litwin,et al.  Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[216]  A. Bogdanove,et al.  TAL effectors: finding plant genes for disease and defense. , 2010, Current opinion in plant biology.